Healthy Skepticism Library
Items published in 2003
There are 1200 items in the Healthy Skepticism Library that were published in 2003.
Page 12 of 12 pages ‹ First < 10 11 12
HSL10469
Richardson R, Shaw I, Nolan S.
A perspective on New Zealand's medicines regulatory environment
International Journal of Pharmaceutical Medicine 2003; 17:(1):17-22
HSL10471
George Wong HC
Potential reactions to patent medicines containing prescription drugs
Allergy and Clinical Immunology International 2003; 15:(3):114-118
HSL10476
First statin patent expires amid OTC speculation
Pharmaceutical Journal 2003; 270:(7247):603
HSL10477
Pharmacists believe EHC is too costly
Pharmaceutical Journal 2003; 270:(7247):603
HSL10478
From the supply of POMs to proposed changes in the BVA'S structure
Veterinary Record 2003; 152:(19):575-578
HSL10479
OFT acts on the supply of POMs
Veterinary Record 2003; 152:(19):574
HSL10480
Schulze J, Raasch W, Siegers CP.
Toxicity of kava pyrones, drug safety and precautions--a case study.
Phytomedicine 2003; 10:
HSL10484
New therapies drive up cost of GI medications
Drug Benefit Trends 2003; 15:6-7
HSL10498
Bad medicine
Veterinary Record 2003; 152:(16):481
HSL10499
Vet medicines monopoly to be broken
Pharmaceutical Journal 2003; 270:(7245):534
HSL10500
Cheng JWM.
Bosentan
Heart Disease 2003; 5:(2):161-169
HSL10504
How genetics could change pharmacy
Pharmaceutical Journal 2003; 270:(7244):508-509
HSL10505
Medicine imports and exports rising
Pharmaceutical Journal 2003; 270:(7244):501
HSL10506
Hemels MEH, Bennett HA, Bonari L, Han D, Traverso ML, Einarson TR.
HOPE study impact on ACE inhibitors use
Annals of Pharmacotherapy 2003; 37:(5):640-645
HSL10507
Maskrey N, Jackson C, Critchlow H.
Support to consider the resource implications of NICE guidance
Journal of Clinical Excellence 2003; 4:(3):306-309
HSL10508
Toop L, Richards D, Dowell T.
The leadership role of general practice in public health: advocating a ban of direct-to-consumer advertising of prescription drugs in New Zealand; 'Possums in the headlights?'.
British Journal of General Practice 2003; 53:(489):342-345
http://www.ingentaconnect.com/content/rcgp/bjgp/2003/00000053/00000489;jsessionid=1dei97cpjj6ai.henrietta?
HSL10510
Wolfe SH.
Ephedra - Scientific evidence versus money/politics
Science 2003; 300:(5618):437
HSL10511
Slade RFJ.
Why the change from 14-disk to 15-disk packs? [3]
Pharmaceutical Journal 2003; 270:(7243):476
HSL10512
DTB advocates prescription of injectable adrenaline for children
Pharmaceutical Journal 2003; 270:(7242):427
HSL10514
Manufacturer claims superior action for new statin
Pharmaceutical Journal 2003; 270:(7242):427
HSL10515
Supplementary prescribing legal from next week
Pharmaceutical Journal 2003; 270:(7242):424
HSL10517
Links.
Compliance Policy Guide on Chapter 4 Human Drugs: Section 460.200 Pharmacy Compounding.
J Pain Palliat Care Pharmacother 2003; 17:(1):99-106
HSL10518
Hildebrand JR.
Report from the USA
Pharmazeutische Industrie 2003; 65:(3):247-251
HSL10520
Theodorou AA.
How 3-tier plan design and other strategies yielded $1.6 billion in cost savings
Drug Benefit Trends 2003; 15:(3):45-54
HSL10521
IJPP given a new look and is now fully available online
Pharmaceutical Journal 2003; 270:(7241):410-411
HSL10522
Armendariz M, Armendariz M, Jaio N, Gorostiza I.
Impact of new non-steroid anti-inflammatory drugs in Primary Care prescription
Pharmaceutical Care Espana 2003; 5:(1):29-38
HSL10523
Roy V, Goyal RK.
Of societies and issues (multiple letters)
Indian Journal of Pharmacology 2003; 35:(2):116-118
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=35&issue=2&spage=116
HSL10524
Lam W.
Off-label promotion and prescribing of gabapentin [2]
Australian Prescriber 2003; 26:(2):28
HSL10525
Krznaric Z.
Drugs in gastroenterology
Medicus 2003; 11:(1):67-78
HSL10530
Achanta AS.
OTC switch case history evaluation: NicoretteR
Clinical Research and Regulatory-Affairs 2003; 20:(1):15-26
HSL10531
Schmidt RJ.
Generic specifications for standard products needed [16]
Pharmaceutical Journal 2003; 270:(7233):116-117
HSL10532
Scrap contract regulations, says OFT
Pharmaceutical Journal 2003; 270:(7233):103
HSL10533
Dismal science sells pharmacy short
Pharmaceutical Journal 2003; 270:(7233):102
HSL10534
Eberwein B, Schulz R.
Allensbach study phytopharmaceutics in 2002, part 2
Schweizerische Zeitschrift fur GanzheitsMedizin 2003; 15:(2):87-93
HSL10536
Boots keeps its spot as biggest health retailer in Europe
Pharmaceutical Journal 2003; 270:(7240):360
HSL10537
Simmonds H.
The role of the PMCPA explained [13]
Pharmaceutical Journal 2003; 270:(7239):334-335
HSL10541
Robinson K.
A rocky road for generics
BioPharm International 2003; 16:(1):24-26
HSL10542
Moulds RFW.
Good prescribing: Where to next?
Medical Journal of Australia 2003; 178:(5):196-197
HSL10544
Wade OL.
The British National Formulary - Memoirs of a former chairman
Pharmaceutical Journal 2003; 270:(7237):278-281
HSL10545
Kempner N.
Planning ahead: Are customers sick of smoking?
Pharmaceutical Journal 2003; 270:(7237):273
HSL10546
McNulty H.
Putting children first [19]
Pharmaceutical Journal 2003; 270:(7237):269
HSL10547
Mason J.
Is the marketing of pharmaceuticals a matter of style over substance?
Pharmaceutical Journal 2003; 270:(7237):264
HSL10620
Neto A.
Changing pharmacy practice: The Australian experience
Pharmaceutical Journal 2003; 270:(7236):235-236
HSL10623
Murthy JMK.
Some problems and pitfalls in developing countries
Epilepsia 2003; 44:(1):38-42
http://www.blackwell-synergy.com/rd.asp?code=EPI&vol=44&page=38&goto=abstract
HSL10625
Cox AR.
Prescribers need appraisal training programmes [21]
Pharmaceutical Journal 2003; 270:(7234):154
HSL10626
Antiepileptics for migraine prophylaxis only cost-effective with frequent episodes
Expert Review of Pharmacoeconomics and Outcomes Research 2003; 3:(1):5-12
HSL10633
Sweet M.
Gabapentin documents raise concerns about off-label promotion and prescribing
Australian Prescriber 2003; 26:(1):18-19
HSL10635
Dooley M.
Prescribing of warfarin, and brand selection [2]
Journal of Pharmacy Practice and Research 2003; 32:(4):259+261
HSL10636
Lubliner AA.
Are over-the-counter St. John's wort preparations as effective as assumed?
Deutsche Apotheker Zeitung 2003; 143:(1-2):50-52
HSL10638
Call for schering to repay NHS money over Yasmin claims
Pharmaceutical Journal 2003; 270:(7231):42
HSL10639
Pharmaceutical industry promotions criticised
Pharmaceutical Journal 2003; 270:(7231):42
HSL10644
Lucioni C, Mazzi S.
Prescription practice versus consuption standards with reference to proton pump inhibitors in Italy
PharmacoEconomics - Italian Research Articles 2003; 5:(1):3-10
HSL10645
Palmer JBD, Palmer RH.
Alosetron for irritable bowel syndrome [9] (multiple letters)
British Medical Journal 2003; 326:(7379):51-52
HSL10646
A measured response on medicines
Veterinary Record 2003; 152:(1):1-2
HSL10647
Thompson M.
Trends in claims for pharmacists' errors
Pharmaceutical Journal 2003; 270:(7230):
HSL10648
Drug price competition has little effect on NHS buying, PPRS study finds
Pharmaceutical Journal 2003; 270:(7230):
HSL11549
Miller D, Dinan W.
Global public relations and global capitalism
Demers D. Terrorism, Globalization and Mass Communication Spokane, WA: Marquette Books 2003
http://www.amazon.com/Terrorism-Globalization-Mass-Communication-Conference/dp/0922993041/ref=sr_1_1/102-5869202-0212934?ie=UTF8&s=books&qid=1190546162&sr=1-1
HSL11748
Reaves ND.
A model of effective health policy: the 1983 Orphan Drug Act.
J Health Soc Policy 2003; 17:(4):61-71
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17824591
HSL13205
Auvray L, Hensgen F, Sermet C.
La diffusion de l'innovation pharmaceutique en médecine libérale : revue de la littérature et premiers résultats français [Diffusion of pharmaceutical innovation in liberal medicine: revue of literature and first French results.]
Quest écon santé 2003; 73:1-8
http://cat.inist.fr/?aModele=afficheN&cpsidt=15305034
HSL13263
Bero L.
Implications of the tobacco industry documents for public health and policy.
Annu Rev Public Health 2003; 24:267-88
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.140813
HSL13294
Mehrotra A, Dudley RA, Luft HS.
What's behind the health expenditure trends?
Annu Rev Public Health 2003; 24:385-412:
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.141008
HSL16001
Nascimento A.
“AO PERSISTIREM OS SINTOMAS O MÉDICO DEVERÁ SER CONSULTADO”. ISTO É REGULAÇÃO?
INSTITUTO DE MEDICINA SOCIAL RIO DE JANEIRO: UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO 2003
Http://www4.ensp.fiocruz.br/visa/publicacoes/_arquivos/DissertacaoPropagandadeMedicamentos.doc
HSL16334
Blech J
Les inventeurs de maladies. Manœuvres et manipulations de l’industrie pharmaceutique. Paris: Actes Sud 2003
http://martinwinckler.com/article.php3?id_article=577
HSL16339
Greider K
The Big Fix: How the pharmaceutical industry rips off American consumers New York: Public Affairs 2003
http://www.amazon.com/Big-Fix-Pharmaceutical-Consumers-Publicaffairs/dp/1586481851
HSL16343
Healy D
Let them eat Prozac. Toronto: Lorrimer 2003
http://books.google.com.au/books?id=5w64WC_-jbMC&dq=Healy,+David.+Let+them+eat+Prozac.&printsec=frontcover&source=bn&hl=en&ei=g5yYSuG8DpKUkAWstsWrAg&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false
HSL16348
Pignarre P
Le grand secret de l’industrie pharmaceutique Paris: La Découverte 2003
http://www.amazon.fr/grand-secret-lindustrie-pharmaceutique/dp/2707144398
HSL16924
Nascimento AC
'Ao persistirem os sintomas o médico deverá ser consultado'. Isto é regulação?
Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro 2003;
http://www.scielo.br/scielo.php?pid=S0102-311X2006001200023&script=sci_arttext
HSL17363
Egilman D, Kim J, Biklen M.
Proving causation: the use and abuse of medical and scientific evidence inside the courtroom--an epidemiologist's critique of the judicial interpretation of the Daubert ruling.
Food Drug Law J 2003; 58:(2):223-50
http://www.ncbi.nlm.nih.gov/pubmed/12866555
HSL17715
Mahowald M, Bornemann M
Psychological aspects of gifts from drug companies
JAMA 2003; 298:(18):2404-2405
HSL17966
Bromley E, Metzl JM
Book Reviews: Prozac on the Couch: Prescribing Gender in the Era of Wonder Drugs : Duke University Press 2003
HSL18060
Smethurst D
Pharmaceutical medicine: making the leap
BMJ 2003; 327:s161-s162
http://archive.student.bmj.com/issues/04/02/careers/66.php
HSL18063
Moynihan R
Cochrane launches global consultation on drug company sponsorship
BMJ 2003; 327:(7423):1068
http://www.bmj.com/cgi/content/full/327/7423/1068
HSL18065
Dyer O
Lancet accuses AstraZeneca of sponsoring biased research
BMJ 2003; 327:(7422):1005
http://www.bmj.com/cgi/content/full/327/7422/1005-a
HSL18073
Relman A
Book review :Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History by Daniel Vesella
JAMA 2003; 290:(16):2194
http://jama.ama-assn.org/cgi/content/full/290/16/2194
HSL18111
Lynden B
Withdrawal of useful drugs from the market
Aust Prescr 2003; 26:50-1
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/50_51_editorial.htm
HSL18113
Dowden J
The story of one complaint
Aust Prescr 2003; 26:(3):
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/67_complaint.htm
HSL18176
Fava GA
Conflict of interest and the credibility of medical journals
Psychotherapy and Psychosomatics 2003; 12:1
HSL18185
Seaton A
Personal Views: 'There's none so blind as the double blind'.
BMJ 2003; 326:(7394):889
http://www.bmj.com/cgi/content/full/326/7394/889
HSL18190
Rector TS, Finch MD, Danzon, PM, Pauly MV, Manda BS
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Medical Care 2003;
http://www.jstor.org/pss/3767849
HSL18193
Turone F
Italian police investigate GSK Italy for bribery
BMJ 2003; 326:(7386):413
http://www.bmj.com/cgi/content/extract/326/7386/413/a
HSL18225
Top 10 drugs
Australian Prescriber 2003; 26:(1):4
http://www.australianprescriber.com/magazine/20/4/artid/231
HSL18226
Fogg S
Informing the consumer
Aust Prescr 2003; 26:2-3
http://www.australianprescriber.com/magazine/26/1/2/3/
HSL18227
Sweet M
Gabapentin documents raise concerns about off-label promotion and prescribing
Aust Prescr 2003; 26:18-9
http://www.australianprescriber.com/magazine/26/1/18/9
HSL18228
Greed and Gabapentin
Aust Prescr 2003; 26:19
http://www.australianprescriber.com/magazine/26/1/artid/640/
HSL19048
Schwartz LM, Woloshin S.
On the prevention and treatment of exaggeration.
J Gen Intern Med 2003; 18:(2):153-4
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494822/?tool=pubmed
HSL19391
Berndt E, Pindyck R, Azoulay P
Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs
The J Ind Econ 2003; 51:(2):243-270
http://www.nber.org/papers/w7772
HSL19517
Grande D
Cost and Quality of Industry-Sponsored Meals for Medical Residents
JAMA 2003; 290:(9):1150-1151
http://jama.ama-assn.org/content/290/9/1150.3.full
HSL19857
Burton B, Rowell A
Disease Mongering
PR Watch 2003; 10:(1):
http://www.prwatch.org/prwissues/2003Q1/monger.html
HSL19858
Burton B, Rowell A
From Patient Activism to Astroturf Marketing
PR Watch 2003; 10:(1):5
http://www.prwatch.org/prwissues/2003Q1/astroturf.html
HSL19859
Rowell A, Burton B
Clinically Suppressed
PR Watch 2003; 10:(1):7
http://www.prwatch.org/prwissues/2003Q1/suppressed.html
HSL19331
Majumdar SR, McAlister FA, Soumerai SB.
Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.
Am J Med 2003 15; 115:(6):467-72
http://www.ncbi.nlm.nih.gov/pubmed/14567371
HSL19383
Charbit O
[Influence de la publicité pharmaceutique sur la prescription.] Influence of pharmaceutical advertising on prescription
MD Dissertation Toulouse: University Paul Sabatier Toulouse III. 2003
HSL19759
Villanueva P, Peiró S, Librero J, Pereiró I.
Accuracy of pharmaceutical advertisements in medical journals.
Lancet 2003 4; 361:(9351):27-32
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2912118-6/fulltext
HSL19811
Durand M
Reality Check: Is It Newsworthy?
Pharma Exec 2003 Apr
pharmexec.findpharma.com/
HSL19920
Metzl J
'Mother's Little Helper': The Crisis of Psychoanalysis and the Miltown Resolution
Gender & History 2003 Aug15:(2):228–255
http://onlinelibrary.wiley.com/doi/10.1111/1468-0424.00300/abstract
HSL20004
Lexchin J.
The siren call of new drugs.
Expert Rev Pharmacoecon Outcomes Res 2003; 3:(5):513-5
http://www.expert-reviews.com/doi/abs/10.1586/14737167.3.5.513
HSL20041
Goodman B.
All rationalizations large and small.
Am J Bioeth 2003; 3:(3):57-8
http://www.tandfonline.com/doi/abs/10.1162/15265160360706624?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
HSL20068
Huxhagen K
Pharmacy and Drug Companies - An alliance with some problems
Information to Pharmacists 2003 Sep
http://www.computachem.com.au/i2P/emag/Issue19/Article7.shtml
HSL20151
McNee W.
More on DTCA and the cost of asthma inhalers.
N Z Med J 2003 7; 116:(1185):U673
http://www.ncbi.nlm.nih.gov/pubmed/14615811
HSL20152
Griffiths IJ.
Opponents of DTCA need the objectivity they expect of advertisers.
N Z Med J 2003 10; 116:(1183):U641
http://www.ncbi.nlm.nih.gov/pubmed/14581950
Page 12 of 12 pages ‹ First < 10 11 12
